BIO:ON Insight #19 · Oct 6, 2026
Discovery in China, manufacturing in Korea, price benchmarks set by the US
Novartis bets up to $7.8B on China's Abogen for an in-body T-cell engager, CMS finalises GLOBE to tie Medicare Part B benchmarks to foreign prices, and Teva and Samsung Bioepis add six more biosimilars. Discovery in China, manufacturing in Korea, price benchmarks set in the US.
What I learned this week
If I had to put this week in one line: the biotech value chain is dividing up by geography, and every role sits somewhere on it. Korea has a good seat today; whether it stays at manufacturing or climbs another rung is still open. Next time you read a deal headline, ask "where on the chain does this company actually stand?" See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Pipeline Analysis
Novartis bets up to $7.8B on Abogen's mRNA in-body T-cell engager
NovartisAbogen BiosciencesABO2203
- Market Trends
CMS finalises GLOBE, tying Medicare Part B benchmarks to foreign prices
US CMS
- Pipeline Analysis
Teva and Samsung Bioepis expand their alliance to six biosimilars
TevaSamsung Bioepis
AI summary
- 1Novartis is paying China's Abogen $575M upfront, up to $7.8B in total, for ABO2203, an mRNA in-body T-cell engager.
- 2CMS finalised GLOBE, which ties Medicare Part B cost benchmarks to prices in comparable countries from January 2027.
- 3Teva and Samsung Bioepis will co-develop and sell up to six biosimilars, their third deal in 2026.
Relevant rolesBDMarket accessCMC & QARegulatory affairs
Summary and tags generated by AI from the issue text.
References
- 1.Novartis bets up to $7.8B on Abogen's mRNA in-body T-cell engager (opens in a new tab)
Fierce Biotech, Oct 2, 2026
- 2.CMS locks in GLOBE, bringing most-favored-nation pricing to Medicare Part B (opens in a new tab)
Fierce Healthcare, Sep 30, 2026
- 3.Teva and Samsung Bioepis expand their alliance with six new biosimilars (opens in a new tab)
Fierce Pharma, Oct 2, 2026
Related insights
Other issues covering the same companies, drugs or topics